Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof of concept study of abatacept (Orencia) in individuals at risk of developing inflammatory arthritis
2015-005285-38Phase 2Unknown
- Sponsor
- University of Leeds
- Start
- Jan 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of abatacept in autoimmune arthritis and arthritis (2 arms), sponsored by University of Leeds. Primary endpoint: Incidence of inflammatory arthritis at 48 weeks. Status: unknown.
02
Drugs
abatacept
03
Conditions
autoimmune arthritisarthritis
Beyond the preview
Go deeper on 2015-005285-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005285-38.